专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1997041227A1 PLASMID-BASED VACCINE FOR TREATING ATHEROSCLEROSIS 审中-公开
标题翻译：基于PLASMID的用于治疗甲状腺功能亢进的疫苗
公开(公告)号：WO1997041227A1
公开(公告)日：1997-11-06
申请号：PCT/US1997007294
申请日：1997-05-01
申请人： T CELL SCIENCES, INC. , THOMAS, Lawrence, J.
发明人： T CELL SCIENCES, INC.
IPC分类号： C12N15/12
CPC分类号： C07K14/47 , A61K2039/51 , Y02A50/466
摘要： A plasmid-based vaccine is provided herein based on the combination of DNA segments coding for one or more B cell epitopes of CETP and one or more broad range helper T cell epitopes. Administration of the plasmids as a vaccine to a vertebrate subject provides an immune response to the subject's endogenous CETP and modulation of CETP activity, leading to prevention or reversal of various manifestations of heart disease. The vaccines provide an advantageous strategy for the prevention or treatment of atherosclerosis.
摘要翻译：本文基于编码CETP的一个或多个B细胞表位和一个或多个宽范围辅助T细胞表位的DNA片段的组合在本文中提供基于质粒的疫苗。将作为疫苗的质粒施用于脊椎动物受试者提供对受试者的内源性CETP的免疫应答和CETP活性的调节，导致预防或逆转各种心脏病的表现。疫苗为预防或治疗动脉粥样硬化提供了有利的策略。

2. 发明申请

WO1996034888A1 MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY 审中-公开
标题翻译：胆固醇转运蛋白（CETP）活性的调控
公开(公告)号：WO1996034888A1
公开(公告)日：1996-11-07
申请号：PCT/US1996006147
申请日：1996-05-01
申请人： T CELL SCIENCES, INC. , RITTERSHAUS, Charles, W. , THOMAS, Lawrence, J.
发明人： T CELL SCIENCES, INC.
IPC分类号： C07K14/775
CPC分类号： A61K39/0012 , A61K38/00 , A61K2039/55572 , A61K2039/6037 , C07K14/47 , Y02A50/466
摘要： This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis.
摘要翻译：本发明涉及包含辅助T细胞表位部分和B细胞表位部分的肽，用于引发针对内源性胆固醇酯转移蛋白（CETP）活性的免疫应答，以预防或治疗心血管疾病如动脉粥样硬化。

3. 发明申请

WO1997040022A1 IMMUNOSUPPRESSIVE COMPOUNDS FROM AN ARYLIDENE DIAMIDE ARRAY 审中-公开
标题翻译：来自ARYLIDENE DIAMIDE ARRAY的免疫抑制化合物
公开(公告)号：WO1997040022A1
公开(公告)日：1997-10-30
申请号：PCT/US1997006969
申请日：1997-04-25
申请人： T CELL SCIENCES, INC. , ARQULE, INC. , HOGAN, Joseph, C. , LIN, Augustine, Y.-T. , UMLAUF, Scott, W.
发明人： T CELL SCIENCES, INC. , ARQULE, INC.
IPC分类号： C07D241/02
CPC分类号： C07D295/185 , C07C237/22 , C07C2602/10 , C07D333/38 , C07D409/12
摘要： Certain novel chemical compounds which inhibit T cell activation and proliferation are disclosed. The compounds were selected from an array of arylidene diamide structures using a combination of assays. The compounds are capable of reducing the activation of T cells by 30 % or more compared to the level of activation in the absence of the compound. The compounds, furthermore, are less toxic than currently used inhibitors, such as cyclosporin A.
摘要翻译：公开了抑制T细胞活化和增殖的某些新型化合物。使用测定的组合从芳基二酰胺结构的阵列中选择化合物。该化合物与不存在化合物时的活化水平相比，能够将T细胞的活化降低30％或更多。此外，化合物比目前使用的抑制剂如环孢菌素A毒性小。

4. 发明申请

WO1992010205A1 SYNERGISTIC COMPOSITIONS OF SOLUBLE COMPLEMENT RECEPTORS AND COMPOUNDS THAT INHIBIT COMPLEMENT AND/OR SUPPRESS IMMUNE ACTIVITY 审中-公开
标题翻译：可溶性补体受体的协同组合物和禁止补充和/或抑制免疫活性的化合物
公开(公告)号：WO1992010205A1
公开(公告)日：1992-06-25
申请号：PCT/US1991009300
申请日：1991-12-06
申请人： T CELL SCIENCES, INC. , MARSH, Henry, C., Jr. , KUNG, Patrick, C.
发明人： T CELL SCIENCES, INC.
IPC分类号： A61K37/48
CPC分类号： C07K14/705 , A61K31/343 , A61K31/41 , A61K38/166 , A61K38/1709 , A61K38/177 , A61K38/482 , A61K38/49 , A61K45/06 , A61K2300/00
摘要： The present invention relates to synergistic therapeutic compositions of synergistic combinations of organic and biological compounds which inhibit complement and/or possess immunosuppressive activity, and the therapeutic uses thereof. The organic compounds of the invention are compounds which exhibit immunosuppressive and/or anti-inflammatory activity. Such organic compounds include but are not limited to K-76, K-76 COOH and derivatives and synthetic analogs thereof, antimetabolites, antimitotic drugs, cyclosporine, steroids, and non-steroidal anti-inflammatory agents. In a particular aspect, the organic compounds of the invention include substituted dihydrobenzofurans, substituted and unsubstituted spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates which exhibit such inhibitory ativities. The biological compounds of the invention are complement receptors or fragments thereof and soluble members of the complement receptor family that contain the conserved SCR motif and that are able to inhibit complement activity. The biological compounds exhibit at least one of the functions associated with complement receptors and/or SCR containing proteins. The invention relates to the use of mixtures of these compounds for therapy of immune and/or inflammatory disorders.
摘要翻译：本发明涉及抑制补体和/或具有免疫抑制活性的有机和生物化合物的协同组合的协同治疗组合物及其治疗用途。本发明的有机化合物是具有免疫抑制和/或抗炎活性的化合物。这些有机化合物包括但不限于K-76，K-76 COOH及其衍生物和合成类似物，抗代谢物，抗有丝分裂药物，环孢霉素，类固醇和非甾体抗炎剂。在一个具体方面，本发明的有机化合物包括取代的二氢苯并呋喃，取代和未取代的螺苯并呋喃-2（3H） - 环烷烃及其开链中间体，其表现出这种抑制活性。本发明的生物化合物是补体受体或其片段和补体受体家族的可溶性成员，其含有保守的SCR基序并能够抑制补体活性。生物化合物显示与补体受体和/或含SCR蛋白相关的功能中的至少一个。本发明涉及这些化合物的混合物用于治疗免疫和/或炎性疾病的用途。

5. 发明申请

WO1994017822A1 PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS 审中-公开
标题翻译： sCR1和其他补充性抑制性蛋白质的脉冲施用
公开(公告)号：WO1994017822A1
公开(公告)日：1994-08-18
申请号：PCT/US1994001405
申请日：1994-02-08
申请人： T CELL SCIENCES, INC. , REGENTS OF THE UNIVERSITY OF MINNESOTA , LEVIN, James, L. , REGAL, Jean, F. , TOTH, Carol, A.
发明人： T CELL SCIENCES, INC. , REGENTS OF THE UNIVERSITY OF MINNESOTA
IPC分类号： A61K37/64
CPC分类号： A61K9/0078 , A61K38/00 , C07K14/705
摘要： The present invention relates to formulations for pulmonary administration by inhalation that comprise a complement inhibitory protein, and uses thereof in the prophylactic or therapeutic treatment of diseases or disorders involving complement, especially diseases or disorders of the lung. In particular, the proteins are complement receptors of fragments thereof or soluble members of the complement receptor family that contain the conserved SCR motif and that are able to inhibit complement activity. More particularly the present invention relates to the direct treatment of certain complement related lung disorders by administering complement receptor proteins via the pulmonary route, in particular, direct delivery to the lungs of a complement receptor protein by aerosolization and subsequent inhalation. The invention also relates to use of a complement inhibitory protein to treat bronchoconstriction or anaphylaxis, or both.
摘要翻译：本发明涉及包含补体抑制蛋白的吸入肺给药制剂及其在预防或治疗性治疗涉及补体，特别是肺疾病或病症的疾病或病症中的用途。特别地，蛋白质是其片段的补体受体或补体受体家族的可溶性成员，其含有保守的SCR基序并能够抑制补体活性。更具体地，本发明涉及通过经由肺途径施用补体受体蛋白质，特别是通过气雾化和随后的吸入直接递送至补体受体蛋白质的肺部来直接治疗某些补体相关性肺病。本发明还涉及补体抑制蛋白用于治疗支气管收缩或过敏反应或两者的用途。

6. 发明申请

WO1994014067A1 DIAGNOSIS AND THERAPY OF SARCOIDOSIS 审中-公开
标题翻译：诊断和治疗SARCOIDOSIS
公开(公告)号：WO1994014067A1
公开(公告)日：1994-06-23
申请号：PCT/US1992010779
申请日：1992-12-14
申请人： T CELL SCIENCES, INC. , WIGZELL, Hans , GRÜNEWALD, Johann , JONSON, Carl-Harald , JONES, Nancy
发明人： T CELL SCIENCES, INC.
IPC分类号： G01N33/53
CPC分类号： C07K14/7051 , A61K38/00 , C07K16/2809 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/56972 , G01N2800/52
摘要： Sarcoidosis is associated with CD4 T lymphocytes which express the T cell receptor V alpha 2.3 chain. Thus, a method for diagnosing sarcoidosis is provided which comprises contacting cells of a subject with a first monoclonal antibody, or an antigen-binding fragment or derivative, specific for an epitope of the variable region of the T cell receptor V alpha 2.3 chain and detecting the binding of the antibody. Also provided is a method for treating sarcoidosis in which a monoclonal antibody, or an antigen-binding fragment or derivative thereof, specific for an epitope of the variable region of the T cell receptor V alpha 2.3 chain is administered. Sarcoidosis is also treated by administering a therapeutically effective amount of a protein or a peptide comprising an amino acid sequence of the variable region of the T cell receptor V alpha 2.3 chain, or a functional derivative of the protein or peptide, or an antisense oligonucleotide which is complementary to the T cell receptor V alpha 2.3 mRNA.
摘要翻译：结节病与表达T细胞受体Vα2链的CD4 + T淋巴细胞有关。因此，提供了一种用于诊断结节病的方法，其包括使受试者的细胞与特异于T细胞受体Vα2链的可变区的表位的第一单克隆抗体或抗原结合片段或衍生物接触并检测抗体的结合。还提供了治疗结节病的方法，其中施用特异于T细胞受体Vα2链的可变区的表位的单克隆抗体或其抗原结合片段或衍生物。还可以通过施用治疗有效量的蛋白质或包含T细胞受体Vα2链的可变区的氨基酸序列或蛋白质或肽的功能性衍生物的肽或反义寡核苷酸来治疗结节病，与T细胞受体Vα2.3mRNA互补。

7. 发明申请

WO1997039722A2 METHOD OF ISOLATING REGULATORS OF T CELL ACTIVATION 审中-公开
标题翻译：隔离T细胞活化调节因子的方法
公开(公告)号：WO1997039722A2
公开(公告)日：1997-10-30
申请号：PCT/US1997007052
申请日：1997-04-25
申请人： T CELL SCIENCES, INC. , LIN, Augustine, Y.-T. , UMLAUF, Scott, W. , BATZER, Andreas, G.
发明人： T CELL SCIENCES, INC.
IPC分类号： A61K00/00
CPC分类号： C12Q1/6897 , C07K14/47 , C07K14/4702 , G01N33/505
摘要： This invention provides a multi-step, high throughput primary screen to identify immune regulators of T cell activation for use as therapeutic agents. Compositions or compounds are screened for their ability to stimulate or inhibit the expression of a reporter gene operatively linked to specific transcriptional control sequences in T cells. A composition or compound identified as an immune stimulator or inhibitor by the primary screen of this invention can then be further characterized to determine the target molecule on which the composition or compound acts to regulate T cell activation and T cell activation-dependent processes such as apoptosis.
摘要翻译：本发明提供一种多步骤，高通量的初级筛选，用于鉴定用作治疗剂的T细胞活化的免疫调节剂。筛选组合物或化合物刺激或抑制与T细胞中特异性转录控制序列有效连接的报告基因表达的能力。然后可以进一步表征由本发明的主筛选被鉴定为免疫刺激剂或抑制剂的组合物或化合物，以确定其上组合物或化合物用于调节T细胞活化和T细胞活化依赖性过程如细胞凋亡的靶分子。

8. 发明申请

WO1995019435A2 T CELL ANTIGEN RECEPTOR V REGION PROTEINS AND METHODS OF PREPARATION THEREOF 审中-公开
标题翻译： T细胞抗原受体V区蛋白及其制备方法
公开(公告)号：WO1995019435A2
公开(公告)日：1995-07-20
申请号：PCT/US1995000408
申请日：1995-01-12
申请人： T CELL SCIENCES, INC. , MAKRIDES, Savvas, C. , KUNG, Patrick, C.
发明人： T CELL SCIENCES, INC.
IPC分类号： C12N15/12
CPC分类号： C07K14/7051 , A61K38/00
摘要： The present invention relates to the production of full length T cell antigen receptor V region proteins. The invention provides for methods of expressing the proteins as well as expression vectors for enhanced production of full length T cell antigen receptor V region proteins. The invention further provides for the V beta 5.3 region protein. The proteins of the invention have uses in the diagnosis and therapy of immune-related disorders.
摘要翻译：本发明涉及全长T细胞抗原受体V区蛋白的产生。本发明提供表达蛋白质的方法以及用于增强全长T细胞抗原受体V区蛋白质产生的表达载体。本发明进一步提供了Vβ3.3区蛋白。本发明的蛋白质在免疫相关疾病的诊断和治疗中具有用途。

9. 发明申请

WO1993018835A1 PROTEIN PURIFICATION 审中-公开
标题翻译：蛋白纯化
公开(公告)号：WO1993018835A1
公开(公告)日：1993-09-30
申请号：PCT/US1993002732
申请日：1993-03-24
申请人： SMITHKLINE BEECHAM CORPORATION , T CELL SCIENCES, INC.
发明人： SMITHKLINE BEECHAM CORPORATION , T CELL SCIENCES, INC. , FOLENA-WASSERMAN, Gail , O'GRADY, John, H. , SMITH, Thomas, M. , LIFTER, John
IPC分类号： B01D15/08
CPC分类号： C07K14/70596 , B01D15/1871 , B01D15/327 , B01D15/34 , B01D15/362 , B01D15/363
摘要： This invention relates to the application of combination chromatography to the purification of complement receptor proteins.

10. 发明申请

WO1989009220A1 THE HUMAN C3b/C4b RECEPTOR (CR1) 审中-公开
标题翻译：人类C3b / C4b受体（CR1）
公开(公告)号：WO1989009220A1
公开(公告)日：1989-10-05
申请号：PCT/US1989001358
申请日：1989-03-31
申请人： THE JOHNS HOPKINS UNIVERSITY , THE BRIGHAM AND WOMEN'S HOSPITAL , T CELL SCIENCES, INC.
发明人： THE JOHNS HOPKINS UNIVERSITY , THE BRIGHAM AND WOMEN'S HOSPITAL , T CELL SCIENCES, INC. , FEARON, Douglas, T. , KLICKSTEIN, Lloyd, B. , WONG, Winnie, W. , CARSON, Gerald, R. , CONCINO, Michael, F. , IP, Stephen, H. , MAKRIDES, Savvas, C. , MARSH, Henry, C., Jr.
IPC分类号： C07H15/12
CPC分类号： C07K16/2896 , A61K38/00 , C07K14/3153 , C07K14/70596
摘要： The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.
摘要翻译：本发明涉及C3b / C4b受体（CR1）基因及其编码蛋白。本发明还涉及包含70个核苷酸的CR1核酸序列及其片段及其编码的肽或包含24个氨基酸的蛋白质。本发明进一步提供CR1蛋白及其片段的表达。本发明的基因和蛋白质在诊断和治疗涉及补体活性的疾病以及各种免疫系统或炎性疾病中具有应用。在下文实施例部分详述的本发明的具体实施方案中，描述了全长CR1 cDNA及其片段的克隆，核苷酸序列和推导的氨基酸序列。还描述了CR1蛋白及其片段的表达。还描述了缺乏跨膜区的分泌型CR1分子的表达。分泌的CR1分子显示可用于减少由炎症引起的损伤和降低心肌梗死面积并防止再灌注损伤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式